Clinical Trial Update: BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of BL22 immunotoxin in hairy cell leukemia patients previously treated with cladribine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• BL22 Immunotoxin (BL22 immunotoxin)

Snippet

Sponsor: MedImmune LLC | Conditions: Leukemia | Phase 2 | Status: COMPLETED